Document:

EX-10.9

 Exhibit 10.9 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 SUPPORT SERVICES AGREEMENT 

THIS SUPPORT SERVICES AGREEMENT (this
“Agreement”) is made and entered into as of January 1, 2021 (the “Effective Date”), by and between JANUX THERAPEUTICS, INC., a Delaware
Corporation (the “Company”), and COI PHARMACEUTICALS, INC., a Delaware Corporation (the “Service Provider”). 

RECITALS 

WHEREAS, the Company possesses the rights to certain intellectual property relating to unnatural base pair biotechnology
(the “Technology”), which it desires to further research and develop; 
 WHEREAS, the Company
currently has limited operational resources and therefore desires to engage Service Provider to provide additional operational resources and services (including personnel, facilities and equipment) intended to assist the Company in pursuing its
business plan of researching and developing the Technology, in each case on the terms and conditions set forth in this Agreement; and 

WHEREAS, Service Provider desires to accept the engagement by the Company. 

NOW, THEREFORE, in consideration of the foregoing premises and the mutual
covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: 

AGREEMENT 
 1. SERVICES.

 1.1 Description of Services. Subject to the terms and conditions of this Agreement, the Company hereby engages Service
Provider, and Service Provider hereby accepts the engagement by the Company, to provide the services described on Exhibit A, or of a similar nature, as may reasonably be requested by the Company and reasonably approved by Service Provider
from time to time following the date hereof (the “Services”). 
 1.2 Service Provider Personnel. For
such time as any personnel of Service Provider are performing Services: (i) such personnel will remain employees of Service Provider and will not be deemed to be employees of the Company for any purpose; and (ii) Service Provider shall be
solely responsible for the payment and provision to such personnel of all wages, bonuses and commissions, employee benefits, and for the withholding and payment of applicable taxes relating to such employment. In addition, Service Provider expressly
acknowledges and agrees that it will be solely responsible for the performance of the Services by all personnel of Service Provider performing any of the Services, and shall at all times cause such personnel to comply with all of the obligations of
Service Provider set forth in this Agreement. 

  
 ***Certain Confidential
Information Omitted 
 1. 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS
BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
  

1.3 General Obligations; Standard of Care. 

(a) Performance Requirements. Service Provider shall provide Services in accordance with the terms of this Agreement and in
accordance with its policies, procedures and practices then in effect, and shall exercise substantially the same care and skill as it exercises in performing similar activities to the Services for itself. 

(b) Separation. Service Provider shall use all reasonable efforts to distinguish the Services performed under this Agreement from
other work the Service Provider performs for itself or any third parties (collectively, “Other Work”), and shall keep records pertaining to such Other Work separately from the records to be maintained pursuant to
Section 5.5 below. 
 (c) Communication. On a regular basis during the Term, the parties shall conduct meetings, either in
person or by telephone or video conference, to discuss the progress and results of the Services. 
 (d) Key Providers. It is
the present intention of Service Provider that substantially all of the Services will be provided and/or overseen by the individuals as specified on Exhibit B hereto (the “Key Providers”), subject to modification from
time to time in consultation with the Company. 
 2. SERVICE FEES. In consideration of Service
Provider’s performance of the Services, the Company shall pay to Service Provider the quarterly fees for Services provided in accordance with the schedule of fees set forth on EXHIBIT A hereto (the “Service
Fees”). Such Service Fees shall be: (i) paid to Service Provider in advance of each calendar quarter during the Term, commencing with an initial payment on the Effective Date in respect of the first calendar quarter during the Term
and continuing thereafter with payments due on the first (1st) business day of each calendar quarter during the Term in respect of each such calendar quarter; and (ii) prorated and refunded (or applied forward to future Service Fees, in each
case as directed by the Company) as necessary for any unearned Service Fees paid during the quarter in which Services are provided. 
 3.
EXPENSES. The Company shall reimburse Service Provider for any reasonable, out-of-pocket expenses incurred by Service Provider in connection with
the provision of the Services, provided Service Provider must submit such written documentation of all such expenses as the Company may reasonably require. Any advance payments by the Company for Service Fees may be credited toward the reimbursement
of any expenses eligible for reimbursement pursuant to the provisions hereof. Within thirty (30) days of the end of each calendar quarter Service Provider will invoice or refund Company (or apply forward to future Service Fees and expense
reimbursements that may become due hereunder, as directed by the Company) as necessary for any under-payment or over payment for such expenses. 
 4.
INDEPENDENT CONTRACTOR RELATIONSHIP. Service Provider’s relationship with the Company shall be solely that of an independent contractor, and nothing in this Agreement shall be construed to
create a partnership, joint venture or employer-employee relationship. Service Provider is not the agent of the Company and is not authorized to make any representation, contract or commitment on behalf of the Company. Service Provider shall not be
entitled to any of the 

  
 ***Certain Confidential
Information Omitted 
 2. 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS
BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
  

benefits that the Company may make available to its employees, such as group insurance, profit-sharing or retirement benefits. Service Provider shall be solely
responsible for all tax returns and payments required to be filed with or made to any federal, state or local tax authority with respect to Service Provider’s and its personnel’s performance of the Services and Service Provider’s
receipt of any compensation pursuant to this Agreement. The Company will regularly report amounts paid to Service Provider by filing Form 1099-MISC with the Internal Revenue Service as required by law. 

5. INFORMATION AND INTELLECTUAL PROPERTY RIGHTS. 

5.1 Confidentiality. Service Provider agrees that it shall at all times take all steps reasonably necessary to hold all
Proprietary Information (as defined below) to which Service Provider has access in trust and confidence, shall not use such Proprietary Information in any manner or for any purpose except as expressly set forth in this Agreement and shall not
disclose any such Proprietary Information to any third party without first obtaining the Company’s express written consent on a case-by-case basis; provided,
however, that Service Provider may disclose certain Proprietary Information, without violating its obligations under this Agreement, to the extent such disclosure is required by a valid order of a court or other governmental body having
jurisdiction, provided that Service Provider provides the Company with reasonable prior written notice of such disclosure and uses its [***] to obtain, or to assist the Company in obtaining, a protective order preventing or limiting the
disclosure and/or requiring that the Proprietary Information so disclosed be used only for the purposes for which the law or regulation required, or for which the order was issued. “Proprietary Information” means (a) the
Company Work Product (as defined below) and (b) any and all other data, information, technology, samples and specimens of the Company or its products, product concepts, technologies, businesses, financial, marketing, clinical or regulatory
affairs, manufacturing processes and procedures, or those of any other third party (including Third-Party Information, as defined below), provided or otherwise made available to Service Provider or to which Service Provider otherwise has access,
either directly or indirectly and whether in written, graphic or verbal form. 
 5.2 Limitations. Service Provider shall not be
obligated to treat information as Proprietary Information if Service Provider can show by competent evidence that such information: 

(a) was already known to Service Provider without any obligations of confidentiality prior to receipt from Company (provided this
exception will not apply to Company Work Product); 
 (b) was generally available to the public or otherwise part of the public domain
at the time of its disclosure to Service Provider; 
 (c) became generally available to the public or otherwise part of the public
domain after its disclosure, other than through any act or omission of Service Provider in breach of any obligation of confidentiality; 

  
 ***Certain Confidential
Information Omitted 
 3. 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS
BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
  

(d) was disclosed to Service Provider, other than under an obligation of confidentiality, by a third party who had no obligation not to
disclose such information to others; or 
 (e) was independently discovered or developed by Service Provider without any use of or
reference to Proprietary Information. 
 As a qualification to the foregoing exceptions, any combination of features or disclosures shall not be deemed to
fall within the foregoing exclusions solely because certain individual features are published or available to the general public or in the rightful possession of a party unless the combination as a whole falls within any of the above exceptions.

 5.3 Third-Party Information. Service Provider understands that the Company has received and will in the future receive from
third parties certain confidential or proprietary information relating to such third parties (collectively, “Third-Party Information”), subject to duties on the Company’s part to maintain the confidentiality of such
Third-Party Information and to use such Third-Party Information only for certain limited purposes. Service Provider agrees to hold all Third-Party Information in confidence and not to disclose to anyone (other than personnel of the Company) or to
use, except in connection with Service Provider’s performance of the Services, any Third-Party Information unless expressly authorized in writing by an officer of the Company. 

5.4 Intellectual Property. 

(a) Ownership. The Company shall own all right, title and interest in and to all Materials, the Technology and Company Work
Product, including, without limitation, all patent, copyright or other intellectual property rights therein, that is conceived or first reduced to practice by Service Provider, either solely or jointly with others, in the course of performing the
Services (collectively, the “Company Intellectual Property”), and neither this Agreement, nor the provision of the Services hereunder, shall give Service Provider any right, title or interest in or to any Company Intellectual
Property. The Company hereby grants to Service Provider a non-exclusive, worldwide, fully-paid, royalty-free license, without the right to sublicense, under the Company Intellectual Property solely as
necessary or appropriate to perform the Services under this Agreement during the Term. Company shall have the sole right to prosecute any patent application covering any Company Intellectual Property and to maintain any patents issued thereon. [***]
of any such patent preparation and filing, prosecuting and maintenance activities in the countries selected by Company. “Materials” means any chemical or biological materials provided by the Company to Service Provider for
use in the Services. “Company Work Product” shall mean any and all results (including data) and products (interim and/or final) of the Services performed by Service Provider, whether tangible or intangible, including, without
limitation, each and every invention (whether or not patentable), discovery, design, drawing, protocol, process, technique, formula, trade secret, device, compound, substance, material, pharmaceutical, method, software program (including without
limitation, object code, source code, flow charts, algorithms and related documentation), listing, routine, manual and specification, whether or not patentable or copyrightable, that are made, developed, perfected, designed, conceived or first
reduced to practice by Service Provider, either solely or jointly with others, in the course of the Services. 

  
 ***Certain Confidential
Information Omitted 
 4. 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS
BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
  

(b) Assignment. Service Provider hereby: (i) assigns to the Company all of its right, title and interest in and to all
Company Intellectual Property; and (ii) designates the Company as its agent for, and grants to the officers of the Company a power of attorney with full power of substitution (which power of attorney shall be deemed coupled with an interest)
solely for the purpose of, effecting the foregoing assignments from Service Provider to the Company. Service Provider will provide all data, results, supporting documents, copies of notebook pages, computer files, etc. necessary for Company to
prepare and file patent applications and will assist Company in obtaining necessary or required documentation and signatures from Service Provider and/or any of its personnel performing the Services. Service Provider further agrees to cooperate with
and (subject to Company’s reimbursement of Service Provider’s reasonable expenses) provide reasonable assistance to the Company to obtain and from time to time enforce any and all current or future intellectual property rights covering or
relating to Company Intellectual Property in any and all jurisdictions. If any intellectual property rights, including moral rights, in the Company Intellectual Property, cannot as a matter of law be assigned by Service Provider to the Company as
provided in this Section 5.4, then: (x) Service Provider unconditionally and irrevocably waives the enforcement of such rights and all claims and causes of action of any kind against Company with respect to such rights; and (y) to the
extent Service Provider cannot as a matter of law make such waiver, Service Provider unconditionally grants to Company an exclusive, perpetual, irrevocable, worldwide, fully-paid license to fully utilize such Company Intellectual Property without
any restriction, including with the right to sublicense. 
 (c) The parties hereto acknowledge that Service Provider commenced
activities of the same nature as the Services set forth on Exhibit A prior to the Effective Date on or about June 27, 2017. The parties’ intention was and is for such activities to be treated as Services under this Agreement in all
respects. Accordingly, the parties hereby agree that any and all such activities shall be deemed Services under this Agreement and any all intellectual property to which Service Provider has or may have any right, title or interest that would
constitute Company Work Product if such activities had constituted Services hereunder at the time they were conducted (“Prior Company Work Product”) shall be treated as Company Work Product for all purposes hereunder,
including, without limitation, the ownership and assignment provisions of this Section 5. Service Provider hereby represents and warrants: (A) that the only personnel of Service Provider that have engaged in activities prior to the
Effective Date that would have constituted Services hereunder had they been performed during the Term are listed on Exhibit B hereto, and all such personnel were employees of Service Provider at the time of performing any such activities and
have executed proprietary information and inventions agreements or otherwise executed assignments in favor of Service Provider which effectively assigned all of such personnel’s right, title and interest to all such Prior Company Work Product
to Service Provider; and (B) as of immediately prior to the Effective Date, all Prior Company Work Product contemplated by this Section 5.4(c) is free from any encumbrance, and Service Provider owns all right, title and interest to and all
of such Prior Company Work Product, which is free and clear of any lien, encumbrance or, to Service Provider’s knowledge, any claim of any right, title or interest of any third party. 

5.5 Records. Service Provider shall maintain records of documents, information, data and materials used or generated in
performance of the Services in a professional manner so as to permit Company to review such records in full in accordance with this Section 5.5 without 

  
 ***Certain Confidential
Information Omitted 
 5. 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS
BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
  

disclosing to Company any third party confidential or proprietary information. Designated representatives of Company shall, upon reasonable notice to Service
Provider, have access to and shall be permitted to review and copy all such records. Following termination of this Agreement, Service Provider shall upon Company’s request deliver to Company one (1) complete copy of such records. 

6. NO CONFLICTING OBLIGATION. Service Provider represents that its entering into this Agreement and
its performance of all of the terms of this Agreement (including the performance of the Services pursuant to this Agreement) do not and will not breach or conflict with any agreement between the Service Provider and any third party, including,
without limitation, any agreement between Service Provider and any third party to keep in confidence any proprietary information of another entity acquired by Service Provider in confidence or in trust prior to the date of this Agreement. Service
Provider agrees not to enter into any agreement that conflicts with this Agreement while this Agreement remains in effect. In addition, except as contemplated by this Agreement, Service Provider will not conduct or participate in, alone or with any
third parties, any research or development activities directed to the Technology without the prior written consent of the Company, which consent shall not be unreasonably withheld. 

7. SERVICE PROVIDER REPRESENTATIONS AND WARRANTIES. 

7.1 Representations and Warranties. Service Provider represents, warrants and covenants that Service Provider: (i) will not
grant, directly or indirectly, any right or interest in the Company Intellectual Property to any other person; (ii) has full right, power, and authority to enter into and perform this Agreement without the consent of any third party, including
the right to grant all assignments and licenses granted by Service Provider in this Agreement; and (iii) will comply with all laws, regulations and ordinances applicable to Service Provider’s performance of the Services and its other
obligations under this Agreement. 
 7.2 Disclaimer of Warranties. EXCEPT AS EXPRESSLY SET FORTH IN SECTION 5.4(C), ARTICLE 6
AND SECTION 7.1 ABOVE, SERVICE PROVIDER MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, CONCERNING THE SERVICES, THE COMPANY INTELLECTUAL PROPERTY, OR THE DELIVERABLES, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT, OR VALIDITY OF ANY CLAIMS OF ANY PATENT OR PATENT APPLICATION ARISING FROM THE SERVICES, WHETHER ISSUED OR PENDING. 

8. INDEMNIFICATION. 

8.1 By Service Provider. Service Provider will defend, indemnify and hold harmless the Company and its affiliates, directors,
officers, employees, consultants and agents (“Company Indemnitees”) from any loss, expense (including reasonable legal counsel fees and expenses), cost, liability or damages to which any Company Indemnitee may become subject
as a result of any claim, demand, action or other proceeding by any third party arising out of a breach of any representation, warranty, covenant or obligation of Service Provider in this Agreement or any

  
 ***Certain Confidential
Information Omitted 
 6. 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS
BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
  

negligence or intentional misconduct by Service Provider or any of its personnel in performing the Services (collectively “Company
Loss”), provided that: 
 (a) Service Provider shall not indemnify any Company Indemnitee for any Company Loss to the
extent the Company Loss is caused by the gross negligence or willful misconduct of Company; 
 (b) Service Provider shall not
indemnify any Company Indemnitee for any Company Loss to the extent the Company Loss is caused by a material breach of this Agreement by Company. 

8.2 By Company. Company agrees to indemnify, defend and hold harmless Service Provider and its Key Providers, officers, employees
and agents (“Service Provider Indemnitees”) from any loss, expense (including reasonable legal counsel fees and expenses), cost, liability or damages to which any Service Provider Indemnitee may become subject as a result of
any claim, demand, action or other proceeding by any third party arising out of Service Provider’s performance of the Services or the use by Company or its designees of any data, findings, or Company Intellectual Property (collectively
“Service Provider Loss”), provided that: 
 (a) Company shall not indemnify any Service Provider Indemnitee
for any Service Provider Loss to the extent the Service Provider Loss is caused by the negligence or willful misconduct of Service Provider; 

(b) Company shall not indemnify any Service Provider Indemnitee for any Service Provider Loss to the extent the Service Provider Loss is
caused by a breach of this Agreement by Service Provider. 
 8.3 Procedure. Any Company Indemnitee or Service Provider
Indemnitee (each, an “Indemnitee”) that intends to claim indemnification under Section 8.1 or 8.2 respectively shall: 

(a) as soon as practicable, and in any event within thirty (30) days, notify the indemnifying party of any known complaint, claim
or injury for which it intends to seek indemnification under this Article 8; and 
 (b) give the indemnifying party sole control of
the defense and/or settlement of any such claim and fully cooperate with the indemnifying party in the defense or settlement of such claim, at the indemnifying party’s expense; provided, however, that no Indemnitee
shall be required to admit fault or responsibility in connection with any settlement. The Indemnitee shall have the right to select and to obtain representation by separate legal counsel at Indemnitee’s own expense. 

(c) Notwithstanding the foregoing, the indemnifying party shall have no obligations with respect to any claim under this Article 8 with
respect to which the Indemnitee seeking indemnification makes any admission, settlement or other communication regarding such claim without the prior written consent of indemnifying party, which consent shall not be unreasonably withheld. 

  
 ***Certain Confidential
Information Omitted 
 7. 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS
BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
  

8.4 Disclaimer of Consequential Damages; Limitation of Liability. NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS AGREEMENT:
(I) IN NO EVENT SHALL EITHER PARTY OR ANY OF ITS AFFILIATES, OR ANY OF THEIR RESPECTIVE DIRECTORS, OFFICERS, EMPLOYEES, CONSULTANTS OR AGENTS BE LIABLE TO THE OTHER PARTY OR ANY OF ITS AFFILIATES FOR INDIRECT, SPECIAL, INCIDENTAL OR
CONSEQUENTIAL DAMAGES OF ANY KIND ARISING IN ANY WAY OUT OF THIS AGREEMENT OR THE RIGHTS GRANTED HEREUNDER, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, REGARDLESS OF WHETHER SUCH PARTY SHALL BE OR HAS BEEN ADVISED, SHALL HAVE REASON TO KNOW OR IN
FACT SHALL KNOW OF THE POSSIBILITY OF THE FOREGOING; PROVIDED, HOWEVER, THAT THE FOREGOING DISCLAIMER OF CONSEQUENTIAL DAMAGES SHALL NOT BE CONSTRUED TO LIMIT EITHER PARTY’S INDEMNIFICATION OBLIGATIONS UNDER THIS ARTICLE 8,
AND (II) IN NO EVENT SHALL SERVICE PROVIDER’S LIABILITY UNDER THIS AGREEMENT EXCEED THE LESSER OF THE AGGREGATE AMOUNT PAID OR PAYABLE BY COMPANY TO SERVICE PROVIDER UNDER THIS AGREEMENT OR TEN MILLION U.S. DOLLARS ($10,000,000). 

9. TERM; TERMINATION. 

9.1 Term. This Agreement shall remain in effect for a period of one (1) year following the Effective Date (the
“Initial Term”). At the end of such Initial Term, this Agreement shall automatically be renewed for one or more additional periods of one (1) year each (each, a “Renewal Term”) unless terminated
by either party by written notice to the other party delivered at least thirty (30) days prior to the end of the Initial Term or any Renewal Term, as applicable. The Initial Term and all Renewal Terms, if any, are collectively referred to
herein as the “Term”. 
 9.2 Termination by Service Provider. This Agreement may be terminated, for any
reason or no reason at all, by Service Provider at any time following the Effective Date by delivering thirty (30) days’ prior written notice to the Company. 

9.3 Termination by the Company. This Agreement may be terminated by the Company: 

(a) for any reason or no reason at all, by the Company at any time following the Effective Date by delivering thirty
(30) days’ prior written notice to Service Provider; or 
 (b) upon Service Provider’s material breach of its
obligations hereunder; provided, however, that the Company shall provide Service Provider written notice of any such claimed breach, describing in reasonable detail the basis for such claim, and Service Provider shall have thirty
(30) days to cure any such breach. 
 9.4 Effect of Termination. The provisions of Sections 4, 5, 7, 8, 9.4 and 10
as well as any outstanding payment or reimbursement obligations of the Company, shall survive any termination of this Agreement. Upon any termination of this Agreement, Service Provider shall promptly deliver to the Company all documents and
other materials of any nature pertaining to the 

  
 ***Certain Confidential
Information Omitted 
 8. 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS
BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
  

Services, together with all documents and other items containing or pertaining to any Proprietary Information, Third-Party Information or Company Intellectual
Property. 
 10. MISCELLANEOUS. 

10.1 Notices. All notices required or permitted hereunder shall be in writing and shall be deemed effectively given:
(i) upon personal delivery to the party to be notified; (ii) when sent by electronic mail or confirmed facsimile if sent during normal business hours of the recipient, and if not, then on the next business day; (iii) five
(5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written
verification of receipt. All communications shall be sent to the Company or to Service Provider, as applicable, at the respective addresses set forth on the signature page to this Agreement or at such other address(es) as the Company or Service
Provider may designate by ten (10) days’ advance written notice to the other party hereto. 
 10.2 Governing Law.
This Agreement shall be governed in all respects by the laws of the State of California, without giving effect to principles of conflicts of laws. 

10.3 Successors and Assigns. The rights and liabilities of the parties hereto shall bind and inure to the benefit of their
respective successors, heirs, executors and administrators, as the case may be; provided, however, that, as the Company has specifically contracted for Service Provider’s services, which services are unique and personal,
Service Provider may not assign or delegate its obligations under this Agreement either in whole or in part to any party without the prior written consent of the Company. The Company may assign its rights and obligations hereunder to any person or
entity who succeeds to all or substantially all of the Company’s operations and who has agreed to be bound by the terms and conditions of this Agreement. Any attempted assignment in violation of the foregoing terms shall be void. 

10.4 Waiver. No failure on the part of any party to exercise any power, right, privilege or remedy under this Agreement,
and no delay on the part of any party in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy and no single or partial exercise of any such power, right, privilege
or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy. No party shall be deemed to have waived any claim arising out of this Agreement, or any power, right, privilege or remedy under this
Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of such party, and any such waiver shall not be applicable or have any effect except
in the specific instance in which it is given. 
 10.5 Amendments. This Agreement may not be amended, modified, altered or
supplemented other than by means of a written instrument duly executed and delivered on behalf of all of the parties hereto. 
 10.6
Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, the parties agree to renegotiate such provision in good faith. 

  
 ***Certain Confidential
Information Omitted 
 9. 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS
BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
  

In the event that the parties cannot reach a mutually agreeable and enforceable replacement in writing for such provision, then: (i) such provision shall
be excluded from this Agreement; (ii) the balance of the Agreement shall be interpreted as if such provision were so excluded; and (iii) the balance of the Agreement shall be enforceable in accordance with its terms. 

10.7 Disclaimer. Except as expressly set forth in this Agreement (including the Exhibits hereto), NEITHER PARTY MAKES ANY
REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, AND EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES OF TITLE, NON-INFRINGEMENT, MERCHANTABILITY, AND FITNESS FOR A PARTICULAR PURPOSE 

10.8 Entire Agreement. This Agreement, including the Exhibits, sets forth the entire understanding of the parties hereto relating
to the subject matter hereof and thereof and supersedes all prior agreements and understandings among or between any of the parties relating to the subject matter hereof and thereof, including but not limited to the Support Services Agreement
previously entered into between the parties as of August 9, 2017. 
 10.9 Counterparts; Execution by Facsimile. This
Agreement may be executed in any number of counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same instrument. The exchange of copies of this Agreement or amendments thereto and of
signature pages by facsimile transmission or by e-mail transmission in portable digital format, or similar format, shall constitute effective execution and delivery of such instrument(s) by the parties and may
be used in lieu of the original Agreement for all purposes. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 ***Certain Confidential
Information Omitted 
 10. 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS
BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
  

IN WITNESS WHEREOF, the parties hereto have executed this SUPPORT
SERVICES AGREEMENT as of the Effective Date. 
  

	
	THE COMPANY:
	
	JANUX THERAPEUTICS, INC.
	
	 /s/ David A. Campbell

	David A. Campbell, PhD
	President and Chief Executive Officer
	
	SERVICE PROVIDER:
	
	COI PHARMACEUTICALS, INC.
	
	 /s/ Jay Lichter

	Jay Lichter
	Director

 [SIGNATURE PAGE TO SUPPORT SERVICES AGREEMENT] 

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS
BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
  

EXHIBIT A 

DESCRIPTION OF SERVICES 

 

					
	 Service
	  	 Description of Services
	  	 Service Fee

	General Administrative Services	  	Services normally associated with the roles of Head of Finance, Sr. Staff Accountant, Human Resources and Facilities, Information Technology, Sr. Financial Analyst, Executive Assistant, Accounts Payable, and Receptionist. Such
Services will include general administrative services required in the ordinary course of the Company’s business which shall include, but is not limited to: (i) bookkeeping and accounting services, including the maintenance of books and
records of the Company’s financial operations in accordance with U.S. generally accepted accounting principles; (ii) reasonable management information services to the Company, including coordination of network services and database
management services, information technology planning services and procurement of general hardware and software; (iii) payroll administration and process services; and (iv) overhead items, including office supplies and telecommunications
services.	  	Cost plus 5%
			
	Facilities Support	  	Service Provider will make available to the Company lab and office space in Service Provider’s facilities located at 11099 North Torrey Pines, Suite 290, La Jolla, California 92037. Quarterly rate to be calculated based on the
percentage of overall square footage of lab and office space utilized by the Company during such calendar quarter and shall include all operating expenses (facilities rent (including common space), utilities, office supplies, phone, internet, shred
services, janitorial, kitchen supplies, bank charges, insurance, legal, tax and accounting, etc.).	  	Cost plus 5%
			
	Supplies and Equipment	  	Ordering, prepayment, invoicing and distribution of laboratory supplies and equipment for use in the R&D Services. Amounts may vary each quarter depending on necessity, with the exact amount to be paid in advance to be set forth
in a preliminary invoice provided by Service Provider to the Company (which amount shall ultimately be subject to further adjustment in accordance with Section 2 hereof).	  	Cost plus 5%

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS
BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
  

EXHIBIT B 

KEY PROVIDERS 

Back Office Support: 
 Jennifer Arthur 

Fran Senchak 
 Fernando Camejo 

Christy Sayers 
 Abby Beers 

Charisse Partridge 
 Curtis Robak 

Lauri SutorEX-10.10

 Exhibit 10.10 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE
COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 CELL LINE LICENSE AGREEMENT 

This Cell Line License Agreement (“Agreement”), effective as of April 19, 2021 (“EFFECTIVE DATE”), is
entered and made by and between WuXi Biologics (Hong Kong) Limited, having an address at Flat/RM826, 8/F Ocean Centre Harbour City, 5 Canton Road TST, Hong Kong (“WuXi Biologics”) and Janux Therapeutics, Inc., having
its principal place of business at 11099 N. Torrey Pines Road, La Jolla, California 92037, USA. WuXi Biologics and Licensee may be referred to herein individually as a “Party” and collectively as the “Parties”. 

The Parties agree as follows: 
 1. Definitions

 1.1 “Affiliate” of a person means any other person that directly or indirectly Controls, is Controlled by, or
is under common Control with, the person, but only for so long as such Control exists. 
 1.2 “Applicable Law” means
all applicable laws, statutes, rules, regulations, guidelines, and directives of the relevant governmental authorities that are applicable to a Party’s activities under this Agreement. 

1.3 “Client Protein” means [***] of interest to Licensee, which is designated by the Licensee to be produced by [***].
[***] is required for each new Client Protein produced by [***], which [***] designating any such additional Client Protein. 
 1.4
“Combination Product” means Drug Product that contains Drug Substance and one or more active ingredients that are not, and do not incorporate, Client Proteins (such other active ingredient(s), “Other
Active(s)”), co formulated, co packaged or otherwise sold together for a single price. 
 1.5 “Confidential
Information” of a Party (the “Disclosing Party”) means all information and materials disclosed by or on behalf of the Disclosing Party to the other Party (the “Receiving Party”) or its Related Persons
(defined below) in connection with this Agreement. The Confidential Information of both Parties includes the existence, terms and objectives of this Agreement, and the nature of any dispute and the outcome of any arbitration proceedings arising out
of or in connection with this Agreement. 
 1.6 “Construct” means a [***] developed by WuXi Biologics that is used
for delivering genetic code and for transfecting and/or transforming the Host Cell Line for purposes of creating the Licensed Cell Line. 

1.7 “Control” over an entity means (a) owning 50% or more of the voting securities or other ownership interests of
such entity or (b) having the power to direct the management or policies of such entity. 
 1.8 “Drug Product”
means a therapeutic product in final dosage form that contains Client Protein produced by the Licensed Cell Line, whether alone or in association with other active or inactive ingredients. 

1.9 “Drug Substance” means bulk Client Protein produced by the Licensed Cell Line, which has not yet been packaged into
its final dosage form. 
  
 ***Certain Confidential Information Omitted

  
 1 

 1.10 “Host Cell Line” means the cell line developed by WuXi
Biologics and designated by WuXi Biologics as the [***] that is transferred or transfected to be the Licensed Cell Line for the manufacture and production of Client Protein for clinical trials and commercial purposes. 

1.11 “Licensed Cell Line” means a transformed or transfected (using WuXi Biologics’ Construct(s)) version of the
Host Cell Line that produces the Client Protein. 
 1.12 “Licensed Know -How
” means, with respect to a particular Client Protein, any and all know-how and non-public information in connection with the applicable Licensed Cell Line owned
or controlled by WuXi Biologics as of the Effective Date or during the term of this Agreement that is used or incorporated in the Process and/or is necessary or reasonably useful to operate the Process. For clarity, the Licensed Know-How includes all such information specified in the Technology Transfer Package. 
 1.13
“Licensed Technology” means the Licensed Know-How and Patent Rights. 
 1.14
“Materials” means the biological materials, including the Licensed Cell Line, provided to Licensee pursuant to the license granted under this Agreement. 

1.15 “Media and Feeds” means any commercially available media and feeds used in the Process. 

1.16 “Net Sales” means, with respect of a Drug Product, the total gross amounts invoiced for commercial sales of such
Drug Product for use in any field by Licensee, its Affiliates, or sublicensees to Third Party customers, less the following deductions actually incurred, allowed, paid, or allocated: 

(i) [***]; 
 (ii)
[***]; 
 (iii) [***]; 

(iv) [***]; 
 (v)
[***]; 
 (vi) [***]; and 

(vii) [***]. 
 In no event
will any particular amount identified above be deducted more than once in calculating Net Sales. Sales or other transfers between Licensee, its Affiliates, or sublicensees shall be excluded from the computation of Net Sales, but the subsequent
resale of such Product to a Third Party shall be included within the computation of Net Sales. 
 The supply of Drug Product for (i) [***],
(ii) [***], (iii) [***], or (iv) [***], in each case, shall be excluded from the computation of Net Sales. 
 If a Drug Product is sold as
part of a Combination Product in a country, the Net Sales with respect to the Combination Product in such country shall be determined by [***]. If the other active ingredient(s) or product(s) in the Combination Product is not sold separately in such
country during the applicable reporting period, Net Sales shall be calculated by [***]. If neither the Drug Product nor the other active ingredient(s) or product(s) were sold separately in the same dosage and dosage form as in the Combination
Product in such country during the applicable reporting period, then [***] shall be used. In the event that the weighted average sale price (by sales volume) of the Drug Product is not available in a given country for any reporting period, then
[***] of the respective products described above (in the same dosage and dosage form as the 
  

***Certain Confidential Information Omitted 

  
 2 

 
Combination Product) in a proxy country to be agreed upon by both Parties will be used (such agreement not be unreasonably withheld, conditioned, or delayed), and if the Parties cannot agree upon
such proxy country, or no such comparable sales figures are available in an appropriate proxy country, Net Sales for the applicable Combination Product shall be [***]. 

1.17 “Patent Rights” means (i) patents and patent applications of any kind throughout the world whether national
or regional, (ii) author certificates, inventor certificates, improvement patents, utility certificates and models and certificates of addition, (iii) divisions, renewals, continuations, continuations in part, reissues, patent disclosures,
improvements, substitutions, confirmations, registrations, validations, re-examinations, additions and extensions of reissue thereof, and (iv) any foreign counterparts of any of the foregoing.
“Patent Rights” shall include all of the foregoing in (i) – (iv) owned or controlled by WuXi Biologics as of the Effective Date or during the term of the Agreement that would be infringed, absent ownership or a license under such
patent rights, by the production of Client Protein using the Process or otherwise in connection with the use of the Licensed Cell Line. The Patent Rights existing as of the Effective Date and necessary for Licensee’s use of the license granted
in Article 2.1 are set out in Appendix II hereto. 
 1.18 “Process” means a process for manufacture of Client Protein
utilizing the Licensed Cell Line, Licensed Know-How, Patent Rights, Materials and Media and Feeds. The Process will be described in the Technology Transfer Package. 

1.19 “Regulatory Approval” means any and all approvals (including pricing and reimbursement approvals), product and
establishment licenses, registrations or authorizations of any kind of a regulatory authority necessary for the development, clinical testing, manufacture, quality testing, supply, use, storage, importation, export, transport, marketing and sale of
a Client Protein (or any component thereof) for use in any country or other jurisdiction. 
 1.20 “Related Persons”
means a Party’s Affiliates and their respective directors, officers, employees, and agents. 
 1.21 “Research Cell
Bank” is a [***]. 
 1.22 “Technology Transfer Package” means all of the information and data describing the
Process and Licensed Know-How, Materials, and Media and Feeds that are necessary or reasonably useful for manufacture of Client Protein using the Licensed Cell Line and the Process. 

1.23 “Third Party” means any person other than the Parties to this Agreement and their respective Affiliates. 

1.24 “Third Party Manufacturer” means (i) a Third Party whose primary business is contract manufacturing, or
(ii) a Third Party who has a contractual arrangement with Licensee or with a sublicensee of Licensee that includes manufacturing of Client Protein and/or Drug Product by such Third Party for Licensee or such sublicensee. 

2. License 
 2.1 License Grant.
WuXi Biologics hereby grants to Licensee and its Affiliate a non-exclusive, worldwide license, with the right to grant sublicenses as provided in Section 2.3, under the Licensed Technology to use the
Licensed Cell Line, Materials, Media and Feeds, and to operate the Process, in each case for the manufacture of Client Protein, including the following licensed activities: 

(i) to make, have made, import and use Client Protein for any and all purposes; and 

(ii) to make, have made, use, sell, have sold, offer for sale, import, keep and otherwise deal in Drug Substance and Drug Product for
any and all purposes. 
  
 ***Certain Confidential Information Omitted

  
 3 

 2.2 Manufacturing Contracting. The Licensee or its Affiliates may contract with a
Third Party Manufacturer for the limited purpose of manufacturing Client Protein, Drug Substance, and Drug Product on behalf of the Licensee or its Affiliates, provided that, such Third Party Manufacturers are bound by the contract to comply with
the terms of this Agreement, and that the Licensee or its Affiliates will remain liable for any Third Party Manufacturers’ breach of this Agreement. 

For the benefit of doubt, a Third Party Manufacturer cannot manufacture Client Protein utilizing the Licensed Cell Line and Licensed
Technology without first being contracted with Licensee, its Affiliates or sublicensee. 
 2.3 Sublicensing. Subject to the terms and
conditions of this Agreement, Licensee shall have the right to grant sublicenses (through multiple tiers) to a Third Party(ies) for the rights granted to Licensee under Section 2.1 of this Agreement. Each sublicense agreement shall be in
writing and provide that the applicable sublicensee is bound by all applicable terms and conditions of this Agreement, and Licensee shall remain liable for any sublicensee’s breach of this Agreement. Licensee shall inform WuXi Biologics in
writing of any and all such sublicenses granted. Licensee shall provide written notice to WuXi Biologics of any sublicense to a Third Party under Section 2.1 within [***] calendar days after granting such sublicense (but excluding wholesalers
and distributors that do not promote the sale of a product). 
 2.4 Except as expressly provided in this Agreement, nothing in this
Agreement shall be deemed to have granted Licensee or its Affiliate or WuXi Biologics or its Affiliate (by implication, estoppel or otherwise) any right, title, license or other interest in or with respect to any intellectual property, know-how or information owned or controlled by the other Party. 
 2.5 The license in
Section 2.1 becomes effective from the date WuXi Biologics completes transfection of the Host Cell Line to generate the Client Licensed Cell Line (the “Commencement Date”). 

3. Transfer of Materials and Licensed Technology 

Promptly following the Commencement Date for a Client Protein, WuXi Biologics shall transfer, disclose and make available, and shall cause its
Affiliates to transfer, disclose and make available, to Licensee, its Affiliates, or any one or more Third Party Manufacturers designated by Licensee, the Technology Transfer Package, including all Materials and Licensed Technology existing as of
such Commencement Date. The Parties shall agree to a written technology transfer plan and schedule for such transfer of the Materials and Technology Transfer Package. In accordance with the agreed technology transfer plan and schedule, WuXi
Biologics will provide reasonable technical assistance to Licensee (or its designee) in the operation of the Process for manufacture of Client Protein using the Licensed Cell Line as necessary to enable Licensee or its designee to replicate the
Process as performed by WuXi Biologics. Such assistance shall be provided at a reasonable service fee to be negotiated by the Parties in good faith. 

4. License Fee 
 As consideration for the
license granted in Section 2 of this Agreement, and the representations and warranties set forth in Section 10 of this Agreement, Licensee agrees to pay WuXi Biologics a fixed one- time, non-creditable (except as provided below), non-refundable license fee of USD $150,000 for the Licensed Cell Line used to product Client Protein(s) (“License
Fee”). WuXi Biologics shall submit an invoice to Licensee for the License Fee within [***] days after the date that WuXi Biologics completes Research Cell Bank generation from the Licensed Cell Line. For clarity, the maximum license fee for
the grant the license of the Licensed Cell Line payable by Licensee under this Section 4 is USD $150,000, regardless of the number of Client Proteins with respect to which Licensee elects to exercise the license. 

5. Cell Line Royalties 
  

***Certain Confidential Information Omitted 

  
 4 

 5.1 As further consideration for the rights granted to Licensee under this Agreement,
during the Royalty Term for a Drug Product, Licensee will pay WuXi Biologics a royalty based on a percentage of Net Sales of Drug Product as follows: 

(a) if, during any calendar year, Licensee, its Affiliate, or a sublicensee has one or more Third Party Manufacturers manufacture one
hundred percent (100%) of its requirements of a particular Client Protein for commercial use, Licensee shall pay to WuXi Biologics a royalty of [***]% of Net Sales of all Drug Products containing such Client Protein during such calendar year; 

(b) if, during any calendar year, Licensee, its Affiliate or any sublicensee has one or more Third Party Manufacturers manufacture a
portion (but less than one hundred percent (100%)) of its requirements of a particular Client Protein for commercial use, and Licensee, its Affiliate, or any sublicensee also manufactures or has WuXi Biologics or any of its Affiliates manufacture
the remainder of its requirements of such Client Protein for commercial use, Licensee shall pay to WuXi Biologics a royalty on Net Sales of all Drug Products containing such Client Protein during such calendar year at the rate determined by
multiplying [***]% by [***]; and 
 (c) if, during any calendar year, Licensee, its Affiliate, or a sublicensee manufactures or has
WuXi Biologics and its Affiliates manufacture one hundred percent (100%) of Licensee’s, its Affiliates, and sublicensees’ requirements of a particular Client Protein for commercial use, Licensee shall have no royalty payment obligations to
WuXi Biologics with respect to Drugs Products containing such Client Protein that are sold in such calendar year. 
 5.2
Notwithstanding Section 5.1 and Section 5.5, with respect to each Client Product, Licensee shall not be obligated to pay royalties to WuXi Biologics on Net Sales of Drug Products or any payment pursuant to the Buy-out Right if Licensee, its Affiliate, or a sublicensee is obligated to manufacture or have manufactured all or a portion of Licensee’s, its Affiliates’, or sublicensees’ requirements of the
relevant Client Protein for commercial use due to: (i) WuXi Biologics, to the extent due to its fault (including any inappropriate or illegal act, any omission or inaction, or any negligence of WuXi Biologics (with exclusion of any
Client’s inappropriate or illegal act, Client’s inaction or omission, or Client’s negligence, or a force majeure event), having failed to supply such Client Protein in accordance with the terms of any commercial supply agreement
between the Parties for such Client Protein; (ii) Licensee having terminated any commercial supply agreement between the Parties for the manufacture and supply of such Client Protein for WuXi Biologics’ uncured material breach of such
agreement; or (iii) WuXi Biologics not being willing to manufacture and supply such Client Protein or not having (a) the manufacturing capacity or GMP-compliant facility(ies) to do so, or
(b) the government permits, including health, safety and environmental permits, necessary for the operation of the facility(ies) where such Client Protein is manufactured. 

5.3 Within [***] days after the end of each calendar quarter in any calendar year for which royalties are payable hereunder, Licensee
shall deliver to WuXi Biologics a written report setting forth on a country-by-country and calendar-quarter basis, Net Sales by Licensee, its Affiliates and sublicensees
in the Territory for each Client Protein during such quarter, the gross amounts invoiced, the total royalties payable, how such royalties were calculated (including an accounting of any reductions in applicable royalty rates and/or deductions in
determining quarterly Net Sales). Following receipt of such royalty report, WuXi Biologics shall issue to Licensee an invoice for the royalty amount payable and Licensee shall pay each such invoice within [***] days after receipt. 

5.4 Any withholding of taxes levied by tax authorities on the payments hereunder shall be borne by WuXi Biologics and deducted by
Licensee from the sums otherwise payable by it hereunder, for payment to the proper tax authorities on behalf of WuXi Biologics. Licensee agrees to cooperate with WuXi Biologics in the event WuXi Biologics claims exemption from such withholding or
seeks deductions under any double taxation or other similar treaty or agreement from time to time in force, such cooperation to consist of providing WuXi Biologics with receipts of payment of such withheld tax or other documents reasonably available
to Licensee (if applicable). 
  
 ***Certain Confidential Information
Omitted 

  
 5 

 5.5 i) Licensee shall have the right (but not the obligation) to buy out its
remaining royalty obligations under Section 5 for a given Client Protein (“Buy- out Right”) by paying to WuXi Biologics the following one-time buy-out payments in two milestones upon the achievement of the corresponding event: 
 5.5.1 USD
$[***] upon [***]; and 
 5.5.2 USD $[***] upon [***]. 

ii) Alternatively, if Licensee wishes to exercise its Buy-out Right after the first commercial launch
of the applicable Drug Product after [***], it may do so upon Licensee’s paying to WuXi Biologics the following one-time buy-out payment: USD $15,000,000. 

iii) For the avoidance of doubt, upon payment by Licensee of the foregoing buy-out payment amount(s)
under either i) or ii), Licensee will be relieved from all future royalty payment obligations under this Section 5 for the applicable Client Protein. 

6. Payment Terms 
 Licensee shall pay WuXi
Biologics’ undisputed invoice(s) within [***] days of receipt by Licensee. Such payments will be made by wire transfer to the account designated by WuXi Biologics. Invoices must be submitted, and payment must be made, without set-off or other deduction of any nature. 
 7. Bank Account Details 

Unless the Parties otherwise mutually agree in writing, and such mutual agreement is set forth in a particular invoice, Licensee shall pay each
invoice in USD by wire transfer to the account designated by WuXi Biologics. 
 8. Restriction 

Licensee agrees that no attempt will be made by or on behalf of Licensee to modify or reverse engineer the Licensed Cell Line or attempt to
reverse engineer, recreate or assemble the Construct(s). Licensee shall only use the Licensed Cell Line in the way as permitted by this Agreement and shall not use or have used the Licensed Cell Line for any purpose other than operating the Process,
the manufacture of Client Protein, Drug Substance and Drug Product, and for other purposes reasonably related to securing Regulatory Approval for the Client Protein and/or Drug Product. Licensee shall not transfer the Licensed Cell Line to any Third
Party except to a permitted sublicensee, as described in Section 2.2 above. For clarity, as between the Parties, the Client Protein, Drug Substance, and Drug Product and all intellectual property rights in the Client Protein, Drug Substance,
and Drug Product, as applicable, are and shall be solely owned by Licensee. 
 9. Indemnity 

9.1 Licensee agrees to defend, indemnify, and hold harmless WuXi Biologics, its Affiliates, and their respective directors, officers,
employees and agents (collectively, the “WuXi Biologics Indemnitees”) harmless from and against any and all liabilities and damages (including reasonable attorneys’ fees) (“Losses”) to which any WuXi Biologics
Indemnitee has been subject as a result of any Third Party claims, demands, suits, or proceedings (“Claims”) to the extent arising out of or resulting from (a) the use of the Licensed Cell Line, Client Protein, Drug Substance
or Drug Product by Licensee or (b) a violation of Applicable Law by any Licensee Indemnitee; provided that Licensee shall have no obligation to indemnify any such Claims to the extent that such Claims arise from (i) negligence or
intentional misconduct of any WuXi Biologics Indemnitee in connection with the Licensed Cell Line (ii) any WuXi Biologics Indemnitee’ breach of this Agreement (including the representations and warranties set forth in Section 9); or
(iii) the use of Host Cell Line components of the Licensed Cell Line or the Licensed Technology. 
  

***Certain Confidential Information Omitted 

  
 6 

 9.2 WuXi Biologics agrees to defend, indemnify, and hold harmless Licensee, its
Affiliates, and their respective directors, officers, employees and agents (“Licensee Indemnitees”) harmless from and against any and all Losses to which any Licensee Indemnitee has been subject as a result of any Claims to the
extent arising out of or resulting from (i) the negligence or intentional misconduct of any WuXi Biologics Indemnitee in connection with the Licensed Cell Line, (ii) any WuXi Biologics Indemnitee’s breach of this Agreement (including
the representations and warranties set forth in Section 9); (iii) a violation of Applicable Law by any WuXi Biologics Indemnitee; or (iv) the use of the Host Cell Line components of the Licensed Cell Line or the Licensed Technology. 

9.3 Each Party shall notify the other Party promptly upon learning of a Claim that is subject to indemnification pursuant to Sections
9.1 or 9.2. The indemnifying Party may control, at its own expense, the defense of the Claim in good faith with counsel of its choice as long as such counsel is reasonably acceptable to the indemnified Party. The indemnified Party shall use
reasonable efforts to cooperate in the defense and may participate at its own expense using its own counsel. No compromise or settlement of any Claim may be made by the indemnifying Party without the indemnified Party’s written consent unless
(a) there is no finding or admission of any violation of law or any violation of the rights of any person and no effect on any other claims that may be made against the indemnified Party, (b) the sole relief provided is monetary damages
that are paid in full by the indemnifying Party, and (c) the indemnified Party’s rights under this Agreement are not adversely affected. 
 10.
Representations and Warranties 
 10.1 WuXi Biologics represents and warrants that: (i) it is a corporation duly organized
validly existing and in good standing under the laws of Hong Kong; (ii) the execution, delivery and performance of this Agreement by WuXi Biologics or its Affiliates have been duly authorized by all necessary corporate action on the part of
WuXi Biologics; (iii) the performance of WuXi Biologics’ obligations under this Agreement will not conflict with its charter documents or result in a material breach of any agreements, contracts or other arrangements to which it is a
party; (iv) WuXi Biologics will not, before termination or expiration of this Agreement, enter into any agreements, contracts or other arrangements that would be materially inconsistent with its obligations under this Agreement; (v) WuXi
Biologics has sufficient facilities, experienced personnel and other capabilities reasonably suited to enable it to perform its obligations under this Agreement; (vi) WuXi Biologics has the right to grant the licenses or sublicenses, as the
case may be, granted under this Agreement; (vii) the Host Cell Line is obtained by WuXi Biologics from legitimate resource and WuXi Biologics has the right to use it for the generation of Licensed Cell Line; (viii) WuXi Biologics is the
sole and exclusive owner of the entire right, title, and interest in and to the Construct used in the Licensed Cell Line (other than any construct used to express the Client Protein if such construct was provided by Licensee), and the Licensed
Technology; (ix) WuXi Biologics’ rights in the Construct, Host Cell Line, Licensed Cell Line (with exclusion of any gene proprietary to Licensee), Materials, and Licensed Technology (collectively, the “WuXi Biologics
Technology”) are valid, subsisting, and enforceable; (x) the WuXi Biologics Technology is free and clear of any encumbrances, liens, pledges, charges, security interests, leases, adverse claims or encumbrances of any kind or character
whatsoever; and (xi) WuXi Biologics has not received any notice that the practice of the Licensed Technology infringes or misappropriates the proprietary rights of any Third Party, and, to the knowledge of WuXi Biologics, the practice of the
Licensed Technology does not infringe or misappropriate the proprietary rights of any Third Party. 
 10.2 Licensee represents and
warrants that: (i) it is a corporation duly organized validly existing and in good standing under the laws of the Delaware; (ii) the execution, delivery and performance of this Agreement by licensee have been duly authorized by all
necessary corporate action on the part of Licensee; (iii) the performance of Licensee’s obligations under this Agreement will not conflict with its charter documents or result in a material breach of any agreements, contracts or other
arrangements to which it is a party; (iv) Licensee has sufficient facilities, experienced personnel and other capabilities reasonably suited to enable it to perform its obligations under this Agreement; and (v) Licensee will not, before
termination or expiration of this Agreement, enter into any agreements, contracts or other arrangements that would be materially inconsistent with its obligations under this Agreement. 

 
 ***Certain Confidential Information Omitted 

  
 7 

 10.3 Disclaimer of Warranties. EXCEPT AS EXPRESSLY SET FORTH HEREIN, THE LICENSED KNOW-HOW, AND LICENSED CELL LINES ARE PROVIDED AND LICENSED TO LICENSEE “AS IS”, AND WUXI BIOLOGICS AND ITS RESPECTIVE AFFILIATES MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OR CONDITIONS OF
ANY KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT THERETO OR TO THE PRODUCTS OR WUXI BIOLOGICS TECHNOLOGY, INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OF THE INTELLECTUAL PROPERTY RIGHTS
LICENSED HEREUNDER, OR NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. 
 11. Confidentiality 

11.1 Subject to the exceptions listed below, during the term of this Agreement and for [***] years thereafter, the Receiving Party
shall, and shall ensure that its Related Persons will, (a) maintain the Disclosing Party’s Confidential Information in confidence, (b) not use such Confidential Information other than in connection with this Agreement, and
(c) not disclose such Confidential Information to any Third Party other than (i) those of its Related Persons that have a need to know such Confidential Information in connection with the activities conducted pursuant to this Agreement and
are obligated to maintain such Confidential Information in confidence, (ii) reasonably required to prosecute patent rights in relation to the Client Protein, Drug Substance, and Drug Product, (iii) in connection with regulatory filings for
the Client Protein or Drug Product, and (iv) to the extent required to be disclosed by Applicable Law or judicial order, or to the extent reasonably necessary to prosecute or defend litigation or arbitration in relation to this Agreement, and,
in either case of this clause (iv), only after the Receiving Party gives the Disclosing Party prior written notice of such requirement and reasonably cooperates with the Disclosing Party’s efforts to limit or avoid such disclosure, to seek a
protective order or secure confidential treatment of the Confidential Information, and/or to seek any other remedies available to the Disclosing Party at law or in equity reducing or limiting such required disclosure. Notwithstanding the foregoing,
the existence of this Agreement and its non-technical terms may be disclosed confidentially to actual or potential investors, financing sources, licensees, and acquirors solely for the purpose of evaluating or
carrying out an actual or potential investment, financing, license collaboration, or acquisition. 
 11.2 The Receiving Party’s
obligations set forth in Section 11.1 do not apply to Confidential Information if (a) the information is public knowledge or becomes public knowledge after disclosure through no act or omission of the Receiving Party or any of its Related
Persons, (b) the information can be shown by the Receiving Party to have been in its possession prior to disclosure, (c) the information was rightfully received on a non-confidential basis from a
Third Party that was not obligated to maintain the information in confidence, or (d) the Receiving Party can show that equivalent information was developed independently by the Receiving Party without reference to the Disclosing Party’s
Confidential Information. 
 11.3 Licensee may disclose the Confidential Information of WuXi Biologics to a Third Party for the
purpose of exercising Licensee’s license rights hereunder (including disclosure to actual or potential licensees, sublicensees, collaborators, contract service providers (including Third Party Manufacturers) and commercial partners with respect
to Client Protein, Drug Substance, or Drug Product), provided that Licensee shall, prior to such disclosure, ensure that each Third Party to which disclosure is to be made is made aware of the obligations contained in this Agreement and agrees to be
subject to obligations of confidentiality and non-use no less onerous than those contained in this Agreement, however, Licensee shall notify WuXi Biologics in writing promptly following any disclosure to a
Third Party to which Licensee has granted a sublicense of rights to use or practice the Licensed Cell Line and Licensed Technology. Any breaches of the obligations of confidentiality and non-use contained in
this Agreement by such Third Party shall be treated as a breach of such obligations by Licensee. 
 11.4 Notwithstanding anything to
the contrary in this Agreement, a Party may disclose this Agreement and its terms, and material developments or material information generated under this Agreement, in securities filings with the U.S. Securities and Exchange Commission (or
equivalent foreign agency) and any rules of stock exchanges where the Parties may be listed to the extent required by Applicable Law after complying with the procedure set forth in this Section 11.4. In such event, the Party 

 
 ***Certain Confidential Information Omitted 

  
 8 

 
seeking such disclosure will prepare a draft confidential treatment request and proposed redacted version of this Agreement to request confidential treatment for this Agreement, and the other
Party will promptly give its input in a reasonable manner in order to allow the Party seeking disclosure to file its request within the timelines proscribed by Applicable Laws. The Party seeking such disclosure shall exercise commercially reasonable
efforts to obtain confidential treatment of this Agreement from the U.S. Securities and Exchange Commission (or equivalent foreign agency) as represented by the redacted version reviewed by the other Party. 

11.5 The provisions of this Section 11 shall survive termination or expiry of this Agreement. 

12. Termination 
 12.1 Term. Unless
terminated earlier by mutual written agreement of the Parties or pursuant to Section 12.2 and 12.3, this Agreement shall continue in effect, on a Client
Protein-by-Client Protein basis, until Licensee exercises the Buy-out Right for the applicable Client Protein under
Section 5.5, in such case, the license grants set forth in Section 2.1 shall become fully paid-up, irrevocable, and perpetual for such applicable Client Protein and corresponding Drug Substances and
Drug Product once Licensee completed the payment of the agreed amount for the Buy-out Right, and no more Royalties will need to be paid to WuXi Biologics for such applicable Client Protein. 

12.2 Voluntary Termination by Licensee. 

Licensee shall have the right to terminate this Agreement upon at least three (3) months’ prior written notice to WuXi Biologics, and
upon payment of all amount due to WuXi Biologics through such termination effective date. 
 12.3 Termination for Default 

(a) Nonpayment. In the event Licensee fails to pay any amounts due and payable to WuXi Biologics hereunder, and fails to make such
payments within thirty (30) days after receiving written notice of such failure, WuXi Biologics may terminate this Agreement immediately upon written notice to Licensee. 

(b) Material Breach. In the event a Party commits a material breach of its obligation under this Agreement and fails to cure that
breach within thirty (30) days after receiving written notice thereof from the other Party, such other Party may terminate this Agreement immediately upon written notice to the breaching Party. 

12.4 Consequence of the Termination. Upon the effective date of the termination referred in this Sections 12.2 and 12.3, the licenses
granted in Section 2.1 shall terminate. Licensee shall, and shall urge its Affiliates, sublicensee, any Third Party Manufacturer to stop all activities referred under the Sections 2.1, 2.2 and 2.3 immediately. 

13. Miscellaneous. 
 13.1
Assignment. This Agreement may not be assigned or otherwise transferred by either Party without the prior written consent of the other Party, which consent shall not be unreasonably withheld, conditioned or delayed; provided, however, that a
Party may, without such consent, assign this Agreement in its entirety (a) to an Affiliate, or (b) to a Third Party in connection with a merger, acquisition, consolidation or a sale involving all or substantially all of the stock or assets
or business of such Party to which this Agreement relates. Any attempted assignment or transfer in violation of this Section 13.1 shall be void. This Agreement shall be binding upon and inure to the benefit of the Parties hereto and their
respective successors and permitted assigns. 
  
 ***Certain Confidential
Information Omitted 

  
 9 

 13.2 Regulatory Assistance. WuXi Biologics will provide assistance relating to the
Licensed Cell Line to Licensee, its Affiliates, and sublicensees, in respect of Licensee’s, its Affiliates’, and sublicensee’s regulatory filing activities for the Client Protein, Drug Substance, and/or Drug Product on commercially
reasonable terms to be agreed by the Parties in good faith for provision of such assistance. 
 13.3 Governing Law. The laws of the
State of New York, U.S., without giving effect to principles of conflict of laws, govern all matters relating to this Agreement. 
 13.4
Arbitration. The Parties shall engage in good faith consultation to resolve any dispute arising out of or in connection with this Agreement. Such consultation will begin immediately after one Party has delivered to the other Party a request for
consultation. If the dispute cannot be resolved within [***] days following the date on which the request for consultation is delivered, then either Party may submit the dispute to JAMS for arbitration to be conducted in accordance with the
Comprehensive Arbitration Rules and Procedures of JAMS in effect at the time of submission. The legal seat or place of arbitration will be New York City, New York. The official language of the arbitration will be English. The tribunal will consist
of one independent arbitrator with experience in biopharmaceutical manufacturing to be appointed by JAMS. The arbitration proceedings will be confidential, and the arbitrator may issue appropriate protective orders to safeguard each Party’s
Confidential Information and except to the extent necessary to confirm, enforce, or challenge an award of the arbitration, to protect or pursue a legal right, or as otherwise required by Applicable Law or regulation or securities exchange, neither
Party nor any arbitrator may disclose the existence, content, or results of any arbitration hereunder without the prior written consent of both Parties. During the course of arbitration, the Parties shall continue to implement the terms of this
Agreement. The arbitral award will be final and binding upon the Parties, and judgment upon the award may be entered in any court of competent jurisdiction for enforcement of the award. The Parties undertake to carry out any award without delay.
Notwithstanding the foregoing, each Party has the right to institute an action in a court of proper jurisdiction for injunctive or other equitable relief pending consultation by the Parties and a final decision by the arbitrator. 

13.5 Entire Agreement. This Agreement constitutes the entire agreement of the Parties with regard to its subject matter and supersedes
all previous written or oral representations, agreements and understandings between WuXi Biologics and Licensee with respect to the subject matter hereof. 

13.6 Amendment. No modification or waiver of any term of this Agreement or any other form of amendment to this Agreement will be binding
unless made expressly in writing and signed by authorized representatives of both Parties. 
 13.7 Severability. If any provision in
this Agreement is held to be invalid, illegal or unenforceable in any respect, then (a) the provision will be replaced by a valid and enforceable provision that achieves as far as possible the intention of the Parties and (b) all other
provisions of this Agreement will remain in full force and effect as if the original Agreement had been executed without the invalidated, illegal or unenforceable provision 

13.8 Notices. All notices, requests, demands, and other communications required under this Agreement must be in writing and will be
deemed to have been given or made and sufficient in all respects when delivered by reputable international courier to the following addresses: 

To Licensee: 
 Janux
Therapeutics Inc 
 11099 N. Torrey Pines Road 

La Jolla, California.92067 
 Attn:
   [***] 
 Tel.:     [***] 

Email:  [***] 
  

***Certain Confidential Information Omitted 

  
 10 

 To WuXi Biologics: 

WuXi Biologics (Shanghai) Co., Ltd. 

Building 1, 288 Fute Zhong Road 

Waigaoqiao Free Trade Zone 

Shanghai, China 200131 
 Attn:
   [***] 
 Tel.:     [***] 

Email:  [***] 
 13.9
Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may be executed by facsimile,
..pdf or other electronically transmitted signatures and such signatures shall be deemed to bind each Party hereto as if they were the original signatures. 

[Signature Page Follows] 
  

***Certain Confidential Information Omitted 

  
 11 

 IN WITNESS WHEREOF, the Parties hereto have caused this CELL LINE LICENSE
AGREEMENT to be duly executed as of the Effective Date set forth above. 
  

									
	WuXi Biologics (Hong Kong) Limited	 		 	Janux Therapeutics, Inc.
					
	By:	 	 /s/ Zhisheng Chen
	 		 	By:	 	 /s/ David Campbell

	Print	 	Name: Zhisheng Chen	 		 	Name:	 	David Campbell
	Title:	 	Director	 		 	Title:	 	CEO

  
 ***Certain Confidential Information
Omitted 

  
 12 

 Appendix I 

List of Service Agreements for Licensee Products 
  

							
	 	  	 Licensee Protein
	  	 Contract (e.g., Master Service Agreements)
	  	 Effective Date

	 1
	  		  		  	
	 2
	  		  		  	
	 3
	  		  		  	
	 4
	  		  		  	
	 5
	  		  		  	

  
 ***Certain Confidential Information
Omitted 

  
 13 

 Appendix II 

Patent Rights 
 [***] 

 
 ***Certain Confidential Information Omitted 

  
 14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}]]